Neuphoria Therapeutics (NEUP) Return on Capital Employed (2024 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Return on Capital Employed of 49.02% for Q1 2026, down 4565.0% year-over-year from 1.1% in Q1 2025, and down 303.33% quarter-over-quarter from 12.15% in Q4 2025.
Neuphoria Therapeutics (NEUP) Return on Capital Employed (2024 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Return on Capital Employed for 3 consecutive years, with 49.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 4565.0% year-over-year to 49.02%; the TTM figure through Mar 2026 stood at 49.02% (down 4565.0% YoY), while the FY2025 annual figure was 4.72%, up 6898.0% from the prior year.
- Return on Capital Employed fell to 49.02% in Q1 2026 per NEUP's latest filing, from 12.15% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.37% in Q1 2025 and bottomed at 82.26% in Q4 2024.
- Historically, Return on Capital Employed has averaged 33.67% across 3 years, with a median of 14.07% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed surged 7011 bps — and 2026, when it slumped 4565 bps.
- Neuphoria Therapeutics' Return on Capital Employed stood at 82.26% in 2024, then soared by 85 bps to 12.15% in 2025, then sank by 303 bps to 49.02% in 2026.
- Business Quant data shows NEUP's Return on Capital Employed at 49.02% in Q1 2026, 12.15% in Q4 2025, and 14.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | -49.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.02% |
| Dec 31, 2025 | -12.15% |
| Sep 30, 2025 | -14.07% |
| Jun 30, 2025 | -4.44% |
| Mar 31, 2025 | -3.37% |
| Dec 31, 2024 | -82.26% |
| Sep 30, 2024 | -70.35% |